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Background: Angiogenesis is crucial for glioblastoma growth, and anti-vascular endothelial growth factor agents are widely used
in recurrent glioblastoma patients. The number of circulating endothelial cells (CECs) is a surrogate marker for endothelial
damage. We assessed their kinetics and explored their prognostic value in patients with recurrent glioblastoma.
Methods: In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent
bevacizumab or lomustine, or bevacizumab plus lomustine. Before treatment, after 4 weeks and after 6 weeks of treatment, CECs
were enumerated.
Results: The number of CECs increased during treatment with bevacizumab plus lomustine, but not during treatment in the
single-agent arms. In patients treated with lomustine single agent, higher absolute CEC numbers after 4 weeks (log10CEC hazard
ratio (HR) 0.41, 95% CI 0.18–0.91) and 6 weeks (log10CEC HR 0.16, 95% CI 0.05–0.56) of treatment were associated with improved
overall survival (OS). Absolute CEC numbers in patients receiving bevacizumab plus lomustine or bevacizumab single agent were
not associated with OS.
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Conclusion: CEC numbers increased during treatment with bevacizumab plus lomustine but not during treatment with either
agent alone, suggesting that this combination induced the greatest vascular damage. Although the absolute number of CECs was
not associated with OS in patients treated with bevacizumab either alone or in combination, they could serve as a marker in
glioblastoma patients receiving lomustine single agent.
Glioblastoma is the most common and most aggressive malignant
primary brain tumour in adults. Angiogenesis is crucial for
glioblastoma growth, and the presence of endothelial proliferation
is a key WHO criterion for diagnosing glioblastoma (Louis et al,
2007). Tumour vessels in glioblastoma are morphologically and
functionally different from normal blood vessels and are
characterised by their high complexity, disorganisation and
leakiness (Jain et al, 2007). Hypoxic glioblastoma tumour cells
are able to interact with endothelial cells and promote angiogenesis
by producing high numbers of vascular endothelial growth factor
(VEGF; Plate et al, 1992; Salmaggi et al, 2003). Therefore, a strong
rationale exists for using anti-VEGF agents such as bevacizumab, a
humanised monoclonal antibody against circulating VEGF, in the
treatment of glioblastoma. Accordingly, numerous clinical trials
have explored the value of bevacizumab in glioblastoma patients
(Friedman et al, 2009; Chinot et al, 2014; Gilbert et al, 2014), but
none of them showed clear survival benefit of single-agent
bevacizumab in newly diagnosed or recurrent glioblastoma.
Treatment response is critical in these studies and in daily
clinical practice and is generally assessed by radiographic response
on MRI. However, besides interobserver (Hayward et al, 2008) and
intraobserver (Provenzale and Mancini, 2012) variability in
radiographic assessments, clear limitations are encountered with
current treatment response evaluation in glioblastoma, especially in
patients treated with anti-VEGF monoclonal antibodies. Most
importantly, the administration of anti-VEGF monoclonal
antibodies may result in radiographic pseudoresponse caused by
the rapid normalisation of abnormally permeable blood vessels
(van den Bent et al, 2009). Although these issues were taken into
account in the revised response assessment criteria proposed by the
Response Assessment in Neuro-Oncology (RANO) working group
(Wen et al, 2010), alternative methods of response assessment
focusing on the extent of angiogenesis could be helpful to guide
prognosis and treatment success in glioblastoma.
Circulating endothelial cells (CECs) are mature endothelial cells
that are present in the peripheral circulation and are presumed to
be a marker of vascular injury (Blann et al, 2005) and angiogenesis.
CECs were shown to have a clinically relevant prognostic value in
various solid tumours (Kraan et al, 2012a). Given the high rate of
angiogenesis in glioblastomas and the lack of prognostic markers
for anti-VEGF treatments in general, we prospectively assessed the
kinetics and prognostic relevance of CECs in the BELOB trial (Taal
et al, 2014). In this randomised phase II trial, patients were treated
for recurrent glioblastoma with bevacizumab plus lomustine, or
with bevacizumab or lomustine single agent.
MATERIALS AND METHODS
Patients and treatment. This prospective study was a side study
of the randomised multi-centre phase II trial from the Dutch
Neuro-Oncology Group (LWNO) ‘BELOB’ (Netherlands Trial
Register ID NTR1929). In-depth information regarding eligibility
criteria, treatment and outcome assessments were described in the
paper regarding the primary clinical end points of the study
(Taal et al, 2014). In brief, patients with recurrent glioblastoma
were stratified according to centre, ECOG performance status and
age, to be subsequently randomised between bevacizumab in
combination with lomustine, bevacizumab single agent or lomus-
tine single agent.
Lomustine was given orally every 6 weeks, for a maximum of six
cycles. Bevacizumab was given intravenously every 2 weeks until
disease progression. One treatment cycle was defined as 6 weeks.
Overall survival (OS) was measured from the day of randomisation
until death from any cause.
The central and local institutional review boards approved the
protocol and all patients provided written informed consent.
Peripheral blood samples for CEC analyses were acquired in
CellSave tubes (Janssen Diagnostics, Raritan, NJ, USA) before the
start of treatment (baseline) and after 4 and 6 weeks of treatment.
Samples were maintained at room temperature and processed
within 96 h of blood collection.
Enumeration of CECs. CECs were enumerated according to our
previously reported flow cytometric approach (Kraan et al, 2012b),
in which we demonstrated excellent reproducibility of the assay
between duplicate CEC samples. The following directly conjugated
monoclonal antibodies were used to identify CEC – CD34-FITC
(clone 8G12; BD Biosciences, San Jose, CA, USA), CD146-APC
(clone 541–10B2; Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) and CD45-PerCP (clone 2D1; BD Biosciences). DRAQ5
(Biostatus Ltd, Shepshed, UK) was used as a cell permeable nuclear
dye to exclude platelets and microparticles. The definition of a
CEC was CD34þ , CD146þ , CD45 and DRAQ5þ .
Samples were acquired on an FACS Canto II or Fortessa flow
cytometer (BD Biosciences) and were later analysed using FCS
Express (De Novo Software, Los Angeles, CA, USA). One
experienced technician (JK) evaluated and checked all the analyses
before the result of the CEC enumeration were considered final to
minimise inter-rater variability.
Statistical analysis. Several time intervals were constructed to
minimise interpatient variability regarding the time of CEC
measurement. For a sample to be eligible as a baseline sample,
the blood should have been drawn at least within 2 weeks before
the start of treatment. A sample was eligible as a 4 weeks sample if
the sample was drawn between days þ 25 and þ 31 after
treatment start, whereas a sample was eligible as a 6 weeks sample
if the sample was drawn before the administration of the second
cycle and between days þ 39 and þ 45 after treatment start.
For comparisons between CEC numbers at baseline versus
during treatment in the same treatment arm, the Wilcoxon signed-
rank test was used. Correlation between corticosteroid use and
CEC numbers was assessed using point biserial correlation.
Correlation between maximum tumour diameter and CEC
numbers was assessed using the Spearman correlation. CEC values
were log10-normalised before inclusion in Cox regression analyses.
For the increase or decrease of CECs relative to baseline, the
logarithm was calculated of the quotient between baseline (t0) and
the appropriate time point (tx), formula: log10(tx/t0).
In case a statistically significant result was observed in the
univariate Cox regression crude hazard ratio (HR) calculation, an
adjusted HR was calculated adjusting for maximum tumour
diameter and corticosteroid use at baseline or after 6 weeks of
treatment. These parameters were not available for 4 weeks after
the start of treatment sample and thus no adjusted HRs were
calculated for this sample. Maximum enhancing tumour diameter
was assessed by RANO criteria (Wen et al, 2010). For a maximum
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diameter to be eligible for adjustment in the multivariate model after
6 weeks of treatment, the corresponding MRI should have been
performed before the administration of the second cycle of lomustine
(only if applicable). All reported P-values are two sided, and a
significance level a¼ 0.05 was used. All data analyses were done
using Stata/SE version 12 (StataCorp LP, College Station, TX, USA).
RESULTS
Patient and treatment characteristics. A total of 153 patients
were enrolled in the BELOB study between December 2009 and
November 2011. From the 148 eligible patients as reported in the
paper regarding the primary end point (Taal et al, 2014), 141
patients were included in this side study. Patient and treatment
characteristics are presented in Table 1. Fifty-one patients were
randomised in the bevacizumab plus lomustine arm, 48 patients
received bevacizumab single-agent therapy, whereas 42 patients
received lomustine single-agent therapy. Only four patients were
still alive at the end of follow-up, and these patients had a median
follow-up of 35.3 months (range 28.9–41.5 months).
CEC measurements and kinetics. A total of 382 samples were
evaluated for the presence of CECs. Thirty samples were excluded
from the analysis because they were not drawn in the appropriate
time interval (n¼ 28) or because they were drawn after the
administration of the second cycle (n¼ 2). Consequently, out of
423 expected samples, 352 samples (83% of expected samples) were
included in the final analysis, of which 129 were eligible as baseline
samples, 119 were eligible as 4 weeks samples and 104 were eligible
as 6 weeks samples (Table 2).
Baseline CEC numbers were not significantly correlated with
corticosteroid use (r¼ 0.06, P¼ 0.54) or the maximum diameter of
the tumour lesion (r¼  0.11, P¼ 0.22). As we expected that CEC
kinetics would differ between the three treatment arms, we
analysed CEC kinetics separately in each treatment arm
(Figure 1). In patients receiving bevacizumab plus lomustine
combination therapy, patients had higher CECs after 4 weeks
(Po0.001) and 6 weeks (Po0.001) of treatment compared with
the baseline value. In contrast, in patients receiving bevacizumab
single agent and in patients receiving lomustine single agent, CECs
at baseline were similar to CECs after 4 weeks and 6 weeks of
treatment.
Association of CEC numbers with OS. The prognostic relevance
of CECs with respect to overall survival in this study was explored
using a Cox regression model. No association was found between
the absolute number of CECs at baseline and overall survival. As
we observed that CEC kinetics differed between the three treatment
arms, Cox regression for absolute CEC counts after 4 weeks and
6 weeks of treatment with respect to OS was performed separately
for each treatment arm (Table 3). In patients receiving bevacizu-
mab plus lomustine and bevacizumab single agent, no significant
associations between absolute CEC counts and OS were observed.
However, in patients receiving lomustine single agent, an
association between OS and higher absolute CEC counts at 4
weeks (log10CEC 4 weeks HR 0.41, 95% CI 0.18–0.91) and 6 weeks
(log10CEC 6 weeks HR 0.16, 95% CI 0.05–0.56) was observed. After
addition of data regarding corticosteroid use and the maximum
tumour diameter after 6 weeks of treatment to the model, the CEC
count after 6 weeks was still significantly associated with OS
(log10CEC 6 weeks HR 0.18, 95% CI 0.05–0.74).
Besides the absolute threshold model as described above, we also
analysed whether changes in CECs from baseline to 4 weeks and
baseline to 6 weeks were associated with OS in the Cox regression
model. In contrast to our findings using the absolute CEC numbers
after 4 weeks and 6 weeks of treatment, we did not observe any
association between CEC changes and OS.
DISCUSSION
There is a clear clinical unmet need for alternative response
evaluation during the treatment of glioblastoma. As glioblastomas
are highly angiogenic tumours, we proposed CEC enumeration as a
surrogate marker for endothelial damage and assessed CEC
kinetics and explored their possible prognostic relevance during
the randomised BELOB trial. We observed that CECs increased
only during treatment in patients receiving combination treatment
with bevacizumab plus lomustine. We also found an association
between higher absolute CEC numbers and improved overall
survival during treatment with lomustine single agent, but not in
bevacizumab-treated patients.
Our observation of increased CECs during treatment with
bevacizumab plus lomustine in contrast to the single-agent
treatment arms suggests that there is a synergistic effect of
bevacizumab and lomustine in triggering endothelial damage. The
results from the BELOB study suggested survival benefit from the
combination of bevacizumab and lomustine, as the primary end
point (OS at 9 months) was reached to justify the exploration of
this combination treatment in a phase III trial (Taal et al, 2014).
Our results indicate that this treatment combination may have had
a positive effect in triggering endothelial damage in the
glioblastoma tumour itself. Our observation of increased CECs
during treatment with bevacizumab and lomustine cytotoxic
chemotherapy is in accordance with previous reports in metastatic
breast cancer and advanced colorectal cancer (Bidard et al, 2010;
Simkens et al, 2010), in which CEC numbers were increased after
combination treatment with cytotoxic chemotherapy and
bevacizumab.
During treatment with the single-agent lomustine cytotoxic
chemotherapy, CEC numbers remained stable. Reynes et al (2013)
observed a similar pattern in glioblastoma patients before and after
treatment with cytotoxic chemotherapy and radiotherapy. To our
knowledge, no other studies have reported on CEC changes during
bevacizumab single-agent therapy; therefore, our finding of stable
CECs during bevacizumab single-agent therapy remains to be
confirmed by other studies.
We did not observe an association between baseline CEC counts
and OS. In addition, we explored whether or not absolute CEC
numbers during treatment or the relative changes during treatment
were associated with outcome. During single-agent therapy with
lomustine, an association was revealed between improved OS and
higher absolute CEC numbers after 4 weeks and 6 weeks of
treatment. As we observed the association between CECs and OS
in the patients receiving single-agent lomustine after both 4 weeks
Table 1. Baseline patient characteristics (n¼141)
Parameter Value
Age, median (range) 57 (24–77)
Sex, female (%) 55 (39)
WHO status (%)
WHO 0 40 (28)
WHO 1 86 (61)
WHO 2 15 (11)
Patients using corticosteroids (%) 68 (48)
Maximum enhancing tumour diameter in mm, median (range) 35 (11–93)
Treatment arm (%)
Bevacizumabþ Lomustine 51 (36)
Bevacizumab single agent 48 (34)
Lomustine single agent 42 (30)
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and 6 weeks of treatment, and this association remained
statistically significant in multivariable Cox regression analysis, it
is unlikely that these findings are false positives. Our findings that
CEC changes relative to baseline did not correlate with OS,
suggests that the absolute CEC number, which reflects the extent of
endothelial damage during treatment at a specific point in time, is
more important than the actual pattern of endothelial damage over
time.
The lack of association between baseline CECs and OS is in
contrast to two other glioblastoma studies (Cuppini et al, 2013;
Reynes et al, 2013). It should, however, be noted that in these
studies other CEC enumeration techniques were used. It is known
that the CEC compartment in patients with solid tumours consists
of both tumour-derived endothelial cells (tumour CECs; tCECs)
and normal tissue-derived endothelial cells (normal CECs; nCECs).
There are a few potential pitfalls associated with measuring the
nCEC compartment. Since the nCEC compartment is relatively
large, smaller changes taking place in the tCEC compartment may
be masked. In addition, changes in the nCEC compartment
because of non-tumour-related causes might lead to incorrect
interpretations regarding the tCEC compartment. The use of
tumour-endothelial markers therefore allows more precise tCEC
measurement. Cuppini et al (2013) used a putative tumour-
endothelial-specific marker (CD109) to detect CECs in their study.
The study by Cuppini et al reported decreased CD109-positive
CECs in patients who responded to bevacizumab plus irinotecan
and bevacizumab single agent after 2 months of treatment, whereas
we could not find such associations for the bevacizumab-contain-
ing regimens in our study. Interestingly, although the study by
Cuppini et al did not observe such an association between
CD109-CECs and response in patients receiving cytotoxic
chemotherapy, we observed that higher CEC numbers were
associated with improved OS only in the single-agent lomustine
cytotoxic chemotherapy group. It should be realised, however, that
there are important differences between the used CEC enumera-
tion method by Cuppini et al and our CEC enumeration method,
which may explain differences in prognostic value between our
studies. Cuppini et al investigated an entirely different CEC
population than we did, with no CD146 expression (Mancuso et al,
2014). While they used CD31 to identify a CD109-positive,
CD146-negative CEC population and a separate CD146-positive,
CD109-negative CEC population with no overlap of both markers,
we used CD34 to identify CD146-positive CECs. Apart from these
differences in CEC enumeration techniques, differences in the
chosen fixed time points and differences in treatment regimens
may also explain the differences between our studies. Another
explanation for the differences between our studies may be that
single-agent irinotecan has no proven efficacy in glioblastoma
(Friedman et al, 2009), in contrast to lomustine.
The most likely explanation that can be thought of as to why we
observed prognostic value of CECs in the patients receiving
lomustine single agent but not in patients receiving bevacizumab-
based therapy is our sample size. Although the number of patients
per treatment arm was relatively large for any study evaluating
recurrent glioblastoma patients, only a limited number of patients
were evaluated per treatment arm. This may have provided
insufficient statistical power to associate CEC numbers with OS in
the bevacizumab-based treatment arms. However, we can speculate
on biological mechanisms that may have accounted for the lack of
prognostic value in the bevacizumab-based treatment arms as well.
As CEC numbers remained stable in the whole group of lomustine
single-agent-treated patients, high CEC numbers during treatment
in the lomustine single-agent arm may represent only those
Table 2. Characteristics of CEC measurements per treatment arm
Month of
CEC count n
Median
(CECs per 4ml)
Range
(CECs per 4ml) n
Median
(CECs per 4ml)
Range
(CECs per 4ml) n
Median
(CECs per 4ml)
Range
(CECs per 4ml)
Bevacizumabþ Lomustine Bevacizumab single agent Lomustine single agent
Baseline 47 54 9–282 40 78 7–793 37 52 7–292
4 weeks 43 128 19–2122 41 76 17–1056 35 65 7–2232
6 weeks 39 170 24–1796 38 103 4–1330 32 71 16–442
Abbreviation: CECs¼ circulating endothelial cells.
Table 3. Cox regression absolute CEC numbers
CEC time point and
treatment arm
log10CEC crude
HR (95% CI) P-value log10CEC
Baseline all treatment arms 1.10 (0.68–1.80) 0.69
4 Weeks
bevacizumabþ lomustine
1.21 (0.59–2.50) 0.59
4 Weeks bevacizumab
single agent
1.32 (0.66–2.65) 0.44
4 Weeks lomustine single
agent
0.41 (0.18–0.91) 0.03
6 Weeks
bevacizumabþ lomustine
0.71 (0.27–1.86) 0.49
6 Weeks bevacizumab
single agent
1.09 (0.49–2.46) 0.83
6 Weeks lomustine single
agent
0.16 (0.05–0.56) 0.004a
Abbreviations: CEC¼ circulating endothelial cell; CI¼ confidence interval; HR¼hazard
ratio.
alog10CEC adjusted HR 0.18 (95% CI 0.05–0.74), P¼ 0.02. Adjusted HR was only calculated if
crude HR was significant and adjusted for corticosteroid use and maximum tumour
diameter after 6 weeks of treatment. No data regarding corticosteroid use and tumour
diameter after 4 weeks of treatment were available.
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Figure 1. Box-whisker plots of CEC kinetics during treatment per
treatment arm (boxes show 25th percentile, median and 75th
percentile, whiskers show the lower and upper adjacent values,
according to Tukey. Dots represent outliers).
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patients in whom a larger extent of endothelial damage was present
as a consequence of more lomustine-induced damage of the
tumour. In contrast to the lomustine single-agent arm, CECs
increased in the whole group of patients receiving bevacizumab
plus lomustine, suggesting that endothelial damage occurred in the
majority of these patients. The origin of CECs responsible for the
increased CEC counts (from the tumour vasculature or the normal
vasculature) is however unknown. Endothelial damage of tumour
vessels might have occurred in the majority of patients because of
an improved penetration of lomustine into the tumour, which has
been demonstrated in preclinical experiments using neuroblastoma
xenografts treated with bevacizumab and systemic chemotherapy
(Dickson et al, 2007). Alternatively, combination treatment with
lomustine and bevacizumab might have triggered significant
endothelial damage in normal tissues in addition to tumour tissue,
consequently masking changes in the tCEC compartment. Both
these mechanisms may have made it more challenging to associate
CECs with outcome in the bevacizumab plus lomustine combina-
tion arm, which further stresses the high need for robust assays to
discriminate tCECs from nCECs. The lack of association between
CEC numbers and outcome in the bevacizumab single-agent arm is
probably due to the fact that bevacizumab as a single agent has low
activity in glioblastoma (Taal et al, 2014).
There are several strong points of our study including the
randomised set-up of our study, the high number of collected
samples and the use of OS as the end point for associations with
CECs. However, our study also had some limitations. The number
of patients per treatment was relatively limited. In addition to
limiting the statistical power of associating CEC numbers with OS
in the bevacizumab-based treatment arms as mentioned before, the
limited number of patients prevented a definition of CEC cutoff
points associated with prognosis and did not allow intergroup
comparisons.
Another limitation is that the CEC assay used in our study does
not specifically detect tumour-derived CECs. Our observation that
CECs increased during treatment with bevacizumab plus lomustine
but were not associated with prognosis, may have been caused by
changes occurring in the nCEC compartment, therefore masking
changes in the tCEC compartment. We recently reported that
CD276 is a putative tCEC marker that was expressed more highly
in CECs from patients with glioblastoma than in CECs from
healthy donors (Kraan et al, 2014). We are currently participating
in an EORTC phase III study that compares outcomes following
bevacizumab plus lomustine versus lomustine single agent in
recurrent glioblastoma (trial registry number NCT01290939); it
includes a side study to evaluate the clinical value of CD276þ
tCECs. This will enable us to validate our findings regarding the
prognostic value of CECs and possibly CD276þ tCECs in
glioblastoma patients receiving lomustine single agent. In addition,
as we believe CD276þ tCECs are more sensitive for measuring the
tCEC compartment, we hope to identify the true clinical value in
patients receiving bevacizumab plus lomustine combination
therapy.
Altogether, the results from our study indicate that it may be
worthwhile to further explore CEC enumeration as a marker in
recurrent glioblastoma, as was also suggested by Cuppini et al.
Given the heterogeneity of tumour types and patient populations,
different antitumour agents administered and different CEC
enumeration techniques used, one should nonetheless be careful
in interpreting CEC data between studies (Strijbos et al, 2008;
Kraan et al, 2012a). Consensus is needed on the optimal CEC
enumeration technique, as this would enable researchers to
compare the findings between studies and ultimately take the
application of CECs to the next level. In addition, the initiation of
studies using promising tCEC markers will be essential for CECs to
eventually make it as a reliable and robust biomarker in clinical
oncology.
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